drugset / Trial / NCT04888741
Methods of T Cell Depletion Trial (MoTD)
Phase 2
Recruiting
400 enrolled
University of Birmingham
IMPACT (funded by NHS Blood & Transplant, Anthony Nolan and Leukaemia UK) · collabThe Jon Moulton Charity Trust · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.
Timeline
- Start
- 2021-02-22
- Primary completion
- 2027-08-23
- Completion
- 2027-08-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 50 mg/kg | Intravenous |
| Subject | Cyclosporine | Peptide | — | Intravenous |
| Subject | Sirolimus | Small molecule | 2 mg | Oral |
| Comparator | Thymoglobulin | Protein / enzyme biologic | 2.5 mg/kg | Intravenous |
| Background | Mycophenolate Mofetil | Small molecule | 0.75 g | Intravenous |
| Background | Mycophenolate Mofetil | Small molecule | 1 g | Intravenous |